Antiverse · Pipeline Wireframe
Announcement Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation →
Discuss your target Partnership options
Pipeline

We run our own programs.

A service business licenses its platform. Antiverse bets on it. Wholly-owned and partnered programs across the receptor classes the industry has walked away from.

Partner on a program See the platform
Page purpose — strategy §Required Subpages (/pipeline). Owned programs signal conviction, not just service work. This is the page that separates Antiverse from a CRO in an SVP's mental model.
01Wholly-owned

Internal programs

ProgramTarget classIndicationStageStatus
PAR1 Protease-activated receptor GPCR Cardiovascular
Lead optimisation Owned
IPF program Undisclosed receptor GPCR Pulmonary fibrosis
Hit to lead Owned
PAQR program Progestin-adipoQ receptor PAQR MASH / cardiometabolic
Discovery Owned
Stage bars, not dates. Stage labels age gracefully; dates go stale. Same principle as the news page.
02Partnered

Partner programs

Programs run with pharma partners. Named where permission has been granted; anonymised to therapeutic area where it has not.

ProgramTarget classIndicationStagePartner
Undisclosed Receptor undisclosed GPCR CNS
Lead optimisation Top 15 Pharma
Anti-PD-1 panel Checkpoint Immuno Oncology
Preclinical Top 15 Pharma
CF program Undisclosed Ion channel Cystic fibrosis
Discovery CF Foundation
Partner column — strategy §Trust. Every row that currently says "Top 15 Pharma" is a case study waiting on a sign-off. As permissions land, names replace tiers and the page gets materially stronger.
03Why these targets

Four hundred locks. Three keys.

Over 400 GPCRs and ion channels are implicated in 60+ human diseases. Three FDA-approved antibodies exist against them. None for ion channels. The programs above are chosen from that gap, not from what is easy.

Addressable
400+

GPCRs and ion channels implicated in human disease.

Approved
3

FDA-approved antibodies against the entire class.

Ion channels
0

Approved antibodies. The category is entirely open.

Bring us the target
everyone else gave up on.

Co-development, licensing or full-service. We'll tell you within 48 hours whether it's feasible.

Discuss your target Partnership options